Log in

NASDAQ:ARDX - Ardelyx Stock Price, Forecast & News

-0.48 (-6.25 %)
(As of 02/16/2020 04:00 PM ET)
Today's Range
Now: $7.20
50-Day Range
MA: $7.27
52-Week Range
Now: $7.20
Volume779,493 shs
Average Volume698,523 shs
Market Capitalization$473.76 million
P/E RatioN/A
Dividend YieldN/A
Ardelyx, Inc, a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARDX



Sales & Book Value

Annual Sales$2.61 million
Book Value$1.86 per share


Net Income$-91,300,000.00


Market Cap$473.76 million
Next Earnings Date3/4/2020 (Estimated)

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). The biopharmaceutical company had revenue of $3.01 million for the quarter. View Ardelyx's Earnings History.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Ardelyx.

What price target have analysts set for ARDX?

6 brokerages have issued twelve-month price objectives for Ardelyx's stock. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's share price to reach $11.40 in the next year. This suggests a possible upside of 58.3% from the stock's current price. View Analyst Price Targets for Ardelyx.

What is the consensus analysts' recommendation for Ardelyx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.

Has Ardelyx been receiving favorable news coverage?

Media headlines about ARDX stock have been trending neutral this week, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ardelyx earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Ardelyx.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest in January. As of January 15th, there was short interest totalling 3,940,000 shares, an increase of 42.8% from the December 31st total of 2,760,000 shares. Based on an average trading volume of 890,800 shares, the short-interest ratio is currently 4.4 days. Currently, 6.3% of the shares of the company are short sold. View Ardelyx's Current Options Chain.

Who are some of Ardelyx's key competitors?

What other stocks do shareholders of Ardelyx own?

Who are Ardelyx's key executives?

Ardelyx's management team includes the folowing people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 54)
  • Mr. David Rosenbaum, Chief Devel. Officer (Age 58)
  • Mr. Mark E. Kaufmann, CFO & Treasurer (Age 51)
  • Mr. Jeffrey W. Jacobs, Sr. VP of Technical Operations (Age 56)
  • Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 65)

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (24.52%), RA Capital Management L.P. (8.14%), Renaissance Technologies LLC (3.74%), Marshall Wace LLP (1.74%), State Street Corp (1.35%) and Ikarian Capital LLC (0.98%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Mark Kaufmann, Michael Raab and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Jacobs Levy Equity Management Inc., Tower Research Capital LLC TRC , Blair William & Co. IL and Citigroup Inc.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann and Michael Raab. View Insider Buying and Selling for Ardelyx.

Which institutional investors are buying Ardelyx stock?

ARDX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Marshall Wace LLP, NEA Management Company LLC, Ikarian Capital LLC, J. Goldman & Co LP, Bailard Inc., FMR LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Ardelyx.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $7.20.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $473.76 million and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-91,300,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Ardelyx employs 86 workers across the globe.View Additional Information About Ardelyx.

MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  439 (Vote Outperform)
Underperform Votes:  380 (Vote Underperform)
Total Votes:  819
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel